Abstract: A pedestrian re-identification method includes: obtaining a target video containing a target pedestrian and at least one candidate video; encoding each target video segment in the target video and each candidate video segment in the at least one candidate segment separately; determining a score of similarity between the each target video segment and the each candidate video segment according to encoding results, the score of similarity being used for representing a degree of similarity between pedestrian features in the target video segment and the candidate video segment; and performing pedestrian re-identification on the at least one candidate video according to the score of similarity.

Abstract: A method for identifying a target, a non-transitory computer-readable storage medium, and an electronic device include: acquiring a first image and a second image, the first image and the second image each including a target to be determined; generating a prediction path based on the first image and the second image, both ends of the prediction path respectively corresponding to the first image and the second image; and performing validity determination on the prediction path and determining, according to a determination result, whether the targets to be determined in the first image and the second image are the same target to be determined.

Abstract: The present invention is directed toward novel compounds and novel methods of use of said compounds of the formula (I), useful as nucleocapsid assembly inhibitors for the treatment of viruses, especially but not exclusively, including pregenomic RNA encapsidation inhibitors of HBV for the treatment of Hepatitis B virus (HBV) infection and related conditions. including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.

Abstract: The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.

Abstract: Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

Abstract: A method for the simulation of a circuit is disclosed. The method may include the determination of parasitic circuit elements, and the determination of one or more operational parameters dependent upon at least the parasitic circuit elements. A model of the parasitic circuit elements may then be generated based upon the one or more operational parameters. The circuit may then be simulated using the model of the parasitic circuit elements to determine a performance level of the circuit. At least one active circuit element may be modified in response to determining that the performance level does not meet a goal.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: A method for the simulation of a circuit is disclosed. The method may include the determination of parasitic circuit elements, and the determination of one or more operational parameters dependent upon at least the parasitic circuit elements. A model of the parasitic circuit elements may then be generated based upon the one or more operational parameters. The circuit may then be simulated using the model of the parasitic circuit elements to determine a performance level of the circuit. At least one active circuit element may be modified in response to determining that the performance level does not meet a goal.

Abstract: The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

Abstract: Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

Abstract: The present invention is directed to benzoimidazol-2-yl pyrimidine derivatives useful as histamine H4 receptor modulators and processes for the preparation of such compounds.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

Abstract: Implementations of the present disclosure involve an apparatus and/or method for identifying and classify nodes of an electrical circuit design to account for hold time violations occurring within the circuit. The nodes may be ordered based on a criticality of the nodes that may aid in identifying those nodes of the circuit where hold time violations may be corrected. In one embodiment, the criticality may relate to the number of potentially violating paths that utilize the identified nodes such that corrective measures applied at those nodes may correct several hold time violating paths. In addition, criticality may be scaled utilizing an available buffer library and other timing information.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.